Spoken Alpha
NRXP
NRX Pharmaceuticals, Inc.
Overview
NRx Pharmaceuticals develops novel therapeutics for central nervous system disorders including suicidal depression, PTSD, chronic pain, and schizophrenia. The company's lead candidates—NRX-100 and KETAFREE (preservative-free ketamine formulations) and NRX-101 (an oral combination of D-cycloserine and lurasidone)—are in FDA review for approval.
NRX Pharmaceuticals, Inc is a Healthcare company operating in Biotechnology with a $145.5M market cap.
NRXP missed consensus EPS by 1.0% in Q2 FY2026, reported Aug 13, 2026.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-08-30.
Transcripts
Recent earnings calls
No earnings calls indexed for NRXP yet
We index calls for roughly 3,000 US-listed companies. If you'd like us to add NRXP, reply to your welcome email and we'll prioritize it.
History
Earnings history
- Q2 FY20262026-08-13EPS$-0.18 vs $-0.09-100.0%Rev$1.1M vs ——EODHD
- Q1 FY20262026-05-14EPS$-0.04 vs $-0.11+63.6%Rev$1.1M vs ——EODHD
- Q4 FY20252026-03-23EPS$0.18 vs $-0.08+100.0%Rev$983.0K vs ——EODHD
- Q3 FY20252025-11-13EPS$-0.51 vs $-0.02-100.0%Rev$242.0K vs ——EODHD
- Q2 FY20252025-08-17EPS$-0.98 vs $-0.23-100.0%Rev$0 vs ——EODHD
- Q1 FY20252025-05-14EPS$-0.34 vs $-0.53+35.9%Rev$4.0K vs ——EODHD
- Q4 FY20242025-03-13EPS$-0.77 vs $-0.37-100.0%Rev$4.0K vs ——EODHD
- Q3 FY20242024-11-13EPS$-0.15 vs $-0.66+77.3%Rev$0 vs ——EODHD
- Q2 FY20242024-08-13EPS$-0.75 vs $-0.69-8.7%Rev$0 vs ——EODHD
- Q1 FY20242024-05-13EPS$-0.74 vs $-0.55-34.5%Rev$8.0K vs ——EODHD
- Q4 FY20232024-03-28EPS$-0.50 vs $-0.80+37.5%Rev$8.0K vs ——EODHD
- Q3 FY20232023-11-12EPS$-0.70 vs $-1.15+39.1%Rev$0 vs ——EODHD
- Q2 FY20232023-08-13EPS$-1.20 vs $-1.40+14.3%Rev$0 vs ——EODHD
- Q1 FY20232023-05-14EPS$-0.16 vs $-0.14-14.3%Rev$0 vs ——EODHD
- Q4 FY20222023-03-29EPS$-1.60 vs $-1.45-10.3%Rev$0 vs ——EODHD
- Q3 FY20222022-11-13EPS$-1.40 vs $-1.400.0%Rev$0 vs ——EODHD
- Q2 FY20222022-08-14EPS$-1.10 vs $-1.00-10.0%Rev$0 vs ——EODHD
- Q1 FY20222022-05-15EPS$-0.21 vs ——Rev$0 vs ——EODHD
- Q4 FY20212022-03-30EPS$-0.53 vs ——Rev$0 vs ——EODHD
- Q3 FY20212021-11-14EPS$-0.40 vs ——Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-13 | $-0.18 | $-0.09 | -100.0% | $1.1M | — | — | EODHD |
| Q1 FY2026 | 2026-05-14 | $-0.04 | $-0.11 | +63.6% | $1.1M | — | — | EODHD |
| Q4 FY2025 | 2026-03-23 | $0.18 | $-0.08 | +100.0% | $983.0K | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-0.51 | $-0.02 | -100.0% | $242.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-17 | $-0.98 | $-0.23 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.34 | $-0.53 | +35.9% | $4.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-13 | $-0.77 | $-0.37 | -100.0% | $4.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-0.15 | $-0.66 | +77.3% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.75 | $-0.69 | -8.7% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-0.74 | $-0.55 | -34.5% | $8.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-28 | $-0.50 | $-0.80 | +37.5% | $8.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.70 | $-1.15 | +39.1% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-1.20 | $-1.40 | +14.3% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.16 | $-0.14 | -14.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $-1.60 | $-1.45 | -10.3% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-1.40 | $-1.40 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-1.10 | $-1.00 | -10.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.21 | — | — | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-0.53 | — | — | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-0.40 | — | — | $0 | — | — | EODHD |
Source: EODHD. NRXP reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NRXP.
$ curl https://api.spokenalpha.com/v1/companies/NRXPFAQ
Frequently asked about NRXP
Where can I find NRX Pharmaceuticals, Inc.'s (NRXP) earnings call transcripts?
Spoken Alpha indexes NRXP's earnings call transcripts at https://spokenalpha.com/companies/NRXP. Each call links to attributed speakers and parsed analyst Q&A. NRX Pharmaceuticals, Inc.'s own investor relations page is at https://ir.nrxpharma.com/.
What sector is NRXP in?
NRX Pharmaceuticals, Inc. (NRXP) operates in the Healthcare sector (Biotechnology industry).